Novavax, Inc. (NASDAQ:NVAX – Get Rating) shares were up 8.6% on Friday . The company traded as high as $13.09 and last traded at $12.81. Approximately 122,808 shares changed hands during trading, a decline of 98% from the average daily volume of 7,861,354 shares. The stock had previously closed at $11.80.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on NVAX. JPMorgan Chase & Co. cut shares of Novavax from a “neutral” rating to an “underweight” rating and decreased their price objective for the company from $132.00 to $27.00 in a report on Thursday, September 22nd. StockNews.com upgraded shares of Novavax from a “sell” rating to a “hold” rating in a report on Saturday, November 19th. Cowen decreased their price objective on shares of Novavax to $55.00 in a report on Thursday, October 13th. Jefferies Financial Group began coverage on shares of Novavax in a report on Friday, December 2nd. They set a “hold” rating for the company. Finally, B. Riley decreased their price objective on shares of Novavax from $74.00 to $37.00 and set a “buy” rating for the company in a report on Monday, January 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $92.50.
Novavax Price Performance
The stock’s 50-day moving average price is $15.10 and its 200 day moving average price is $29.49. The firm has a market cap of $964.77 million, a P/E ratio of -0.71 and a beta of 1.89.
Institutional Trading of Novavax
Institutional investors have recently made changes to their positions in the business. US Bancorp DE raised its position in Novavax by 9.0% during the second quarter. US Bancorp DE now owns 2,270 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 187 shares in the last quarter. Geneos Wealth Management Inc. raised its position in Novavax by 14.4% during the second quarter. Geneos Wealth Management Inc. now owns 2,070 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 261 shares in the last quarter. Toroso Investments LLC raised its position in Novavax by 15.3% during the first quarter. Toroso Investments LLC now owns 3,297 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 437 shares in the last quarter. Xponance Inc. raised its position in Novavax by 6.0% during the second quarter. Xponance Inc. now owns 9,218 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 523 shares in the last quarter. Finally, Mascoma Wealth Management LLC bought a new stake in Novavax during the second quarter worth $27,000. Institutional investors own 45.70% of the company’s stock.
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.